Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary

August 8, 2023

NASDAQ US Health Care Biotechnology earnings 41 min

Earnings Call Speaker Segments

Zack Kubow

executive
#1

Thanks, operator. Hello, everybody, and good afternoon. We appreciate your participation in this call covering Corvus Pharmaceuticals' business update and financial results for the second quarter of 2023. Joining us to go over the results and business updates are Richard Miller, our Chief Executive Officer, Leiv Lea, Chief Financial Officer, James Rosenbaum, Senior Vice President of Research, and Ben Jones, Senior Vice President of Regulatory and Pharmaceutical Sciences. Our executive team will begin with prepared remarks, after which we'll take questions. I want to remind all of you that what management says today, along with responses to questions, will contain forward-looking statements. Such statements rest on estimates and assumptions as of today and carry risks and uncertainties that could lead actual results to differ materially from what those statements express or imply, including the risks and uncertainties laid out in Corvus's quarterly report on Form 10-Q, filed with the SEC today, as well as other filings the company periodically makes with the SEC. Except where the law requires it, the company assumes no obligation to publicly update or revise any forward-looking statements. Having said that, I'll hand the call over to Leiv.

Leiv Lea

executive
#2

Thanks, Zack. I'll kick things off with a brief look at how we did financially in the second quarter of 2023, and after that I'll hand things over to Richard for an update on the business. R&D spending came to $4 million during the second quarter of 2023, versus $4.9 million across the same stretch of 2022. That $0.9 million drop mostly stemmed from reduced costs for clinical trials and manufacturing tied to developing mupadolimab, our anti-CD73 antibody. We posted a net loss of $6.5 million in the second quarter of 2023, which includes a $1.3 million non-cash loss connected to Angel Pharmaceuticals, our partner in China. For comparison, the same period in 2022 showed a net loss of $8.4 million, and that figure included a $1.6 million non-cash loss tied to Angel Pharmaceuticals. Total stock compensation expense reached $0.5 million in the second quarter of 2023, against $0.7 million in the comparable period of 2022. At June 30, 2023, Corvus held cash, cash equivalent, and marketable securities amounting to $37 million, whereas at December 31, 2022, that total stood at $42.3 million. Through our at-the-market program, the company sold roughly 2.3 million shares of common stock during the quarter, generating net proceeds of $7.5 million. Turning to what's ahead, we anticipate net cash used in operating activities for the full year 2023 will land somewhere between $20 million and $22 million, which would leave us with a projected cash balance of between $28 million and $30 million at December 31, 2023. As we said last quarter, we keep managing our cash burn rate prudently, concentrating on the opportunities with the most promise and setting up collaborations that assist in supporting development of our product candidates. Given that pattern and our emphasis on soquelitinib, previously known as CPI-818, we think our cash gives us runway into the second half of 2024. Now I'll pass the call to Richard, who will walk through our clinical progress and go into more detail on our strategy and plans.

Richard Miller

executive
#3

Thank you, Leiv. Hello, everyone, and good afternoon. We appreciate your participation in today's call regarding our business update; our attention remains fixed on the considerable chance to create soquelitinib, our selective ITK inhibitor, as a possible innovative method for cancer immunotherapy. During the past few months, we accomplished a number of important milestones that boosted both our assurance and wider enthusiasm for soquelitinib, such as continuing to enroll patients in our Phase 1/1b study for peripheral T-cell lymphoma and sharing further findings from that study at a prominent global lymphoma conference. Next, a highly detailed paper appeared in bioRxiv concerning the chemical characteristics, immune system activity, and how soquelitinib works in preclinical models of blood-related and solid tumors. Third, we filed our data package for an approaching meeting in the third quarter with FDA to talk about our registration approach and suggested phase 3 study for soquelitinib in relapsed peripheral T cell lymphoma, or PTCL. We are still set to launch our phase 3 study before the year ends and intend to begin a monotherapy solid tumor study in the coming months. Furthermore, we are gathering thrilling fresh information about siforadenant, our adenosine A2A receptor inhibitor. Current noteworthy items from this initiative involve finishing the phase 1b segment of a phase 1b/2 study run by the Kidney Cancer Consortium, with movement into the phase 2 segment of the research in first-line treatment of renal cell carcinoma alongside ipilimumab and nivolumab. Preliminary results from this study are expected before the year concludes. Next, a presentation at the Japanese Cancer Association/AACR Joint Meeting about how siforadenant works and its impact on myeloid T-cell interactions. Now I will provide additional specifics on our advancements with soquelitinib and with siforadenant; we keep reinforcing the scientific and clinical basis for the possible application of soquelitinib in cancer immunotherapy, and crucially, are moving forward toward a possible registration Phase III randomized study for T-cell lymphoma. In short, we believe soquelitinib is an extremely unique medication due to these qualities. 1, the capacity to block a clearly specified, highly particular molecular target, the kinase enzyme ITK, without any other recognized notable off-target consequences. two, preliminary clinical information has shown multifaceted impacts on the immune system via its regulation of T-cell differentiation. Three, in clinical practice, we have demonstrated monotherapy antitumor action with lasting reactions in very ill individuals, together with a favorable safety profile under long-term dosing. We consider soquelitinib a possible innovative method for cancer immunotherapy that differs from checkpoint inhibitors and could potentially supplement or work together with checkpoint blockade. We think soquelitinib is first in class, since it is the most advanced and selective ITK inhibitor currently being developed. This could become a significant new therapeutic alternative for individuals whose PTCL has come back, and it also offers a platform possibility spanning many different cancers and immune-related conditions. Our plan remains on schedule for a meeting with the FDA during this quarter, where we will talk about the phase III study we are proposing. We expect that trial to be randomized, enrolling roughly 150 patients in total, and to compare soquelitinib used as a single agent against chemotherapy drugs that represent the current standard of care. Progression-free survival is the primary endpoint we have planned. An interim analysis will be part of the study as well. If our FDA meeting goes well, we intend to launch the Phase III trial prior to the conclusion of this year, and we have already started recruiting possible sites and investigators for it. Up to now, we have brought on board top-tier academic and private institutions that stand out as leaders in lymphoma. A prominent figure in the field serves as our principal investigator, someone with an extensive publication record who has run Phase III studies involving T-cell lymphoma. The newest interim results for soquelitinib were shared at the International Conference on Malignant Lymphoma back in June. As of May 18, 2023, we reported that 30 patients in total had been enrolled in the Phase 1/1b clinical trial for relapsed T-cell lymphoma at the optimal dose of 200 mg given twice daily, and 20 of them could be evaluated for response. In short, among those 20 evaluable patients, three achieved complete responses and three achieved partial responses, and one of the partial responses showed ongoing tumor regression. The data indicated that among patients whose absolute lymphocyte count, or ALC, exceeded 900 per cubic milliliter of blood, objective responses occurred in 6 of 14 patients, while disease control was achieved in 12 of 14 patients. Correlative lab work on blood and tumor tissue verified the mechanism of action, revealing greater tumor infiltration by cytotoxic T cells, along with enhanced cytolytic capacity and a decrease in T-cell exhaustion markers. We take encouragement from both the clinical and laboratory findings and are still enrolling participants in the study. An abstract has been submitted for the ASH annual meeting in December, where we intend to share further details about this trial. Additional interest in our trial came from recently published preclinical data on soquelitinib in bioRxiv, which drew attention to the selective inhibition of ITK that boosts antitumor immune response against hematologic and solid tumors via a novel mechanism of action. The main points from that publication are as follows: soquelitinib, first, is a covalent irreversible inhibitor that selectively binds to and inhibits ITK function while leaving other closely related kinases untouched, such as resting lymphocyte kinase, or RLK. Second, it activates cytotoxic killer cells, which increases how much these cells infiltrate tumors. Third, it diminishes and reverses T-cell exhaustion, producing an immune response that is both more potent and longer lasting. The impact on T-cell exhaustion came as a surprise and tackles a key shortcoming of immune-based therapies currently in use. Resistance to immune checkpoint therapy, and to CAR T-cell therapies as well, is frequently driven in large part by T-cell exhaustion... We additionally discovered that soquelitinib suppressed TH2 T-cell activity along with the generation of TH2 cytokines, which produced TH1 skewing together with the generation of interferon-γ and tumor necrosis factor — cytokines that matter greatly for tumor rejection. According to the publication, soquelitinib generated in vivo antitumor activity across multiple mouse tumor models, among them colon, renal, melanoma, B- and T-cell tumors. Because of these multipronged effects, our expectation is that soquelitinib will show monotherapy activity and also complement or synergize with other immune therapies, for example checkpoint inhibitors. The mechanism studies and results detailed in the bioRxiv publication excite us, and we intend to launch clinical studies assessing single-agent soquelitinib's capacity to boost immune responses against solid tumors. A protocol is developed at this point, and renal cell cancer patients in first or second relapse after frontline checkpoint inhibitor therapy will be our first indication. Evaluating antitumor activity will be this study's primary objective. We have multiple reasons to begin with renal cell cancer in order to establish proof of principle, and other solid tumors are being planned as well. Strong interest in soquelitinib has been voiced by the Kidney Cancer Consortium, which will lead this trial. Lastly, we keep advancing our ITK inhibitor platform for possible application in autoimmune diseases, grounded in findings that soquelitinib inhibits TH2 and TH17 function and the cytokines they secrete.

Richard Miller

executive
#4

These cytokines are central players in numerous inflammatory conditions, meaning this strategy opens up a novel direction for treating immune-related illnesses including atopic dermatitis, asthma, fibrosis, along with numerous other autoimmune allergic conditions. Preclinical findings regarding how soquelitinib performs in autoimmune allergic diseases are slated for publication shortly. Right now, the Kidney Cancer Consortium is in the process of enrolling individuals for a phase 1b/2 clinical study that assesses siforadenant — our inhibitor targeting the adenosine 2A receptor — as a possible first-line treatment for metastatic renal cell cancer, given alongside ipilimumab and nivolumab. The phase 1b safety segment of that study wrapped up successfully, and enrollment is ongoing in the phase two portion, with dosing remaining unchanged. As many as 60 patients are expected to take part in this clinical trial. According to our present timeline expectations, we expect to see initial interim data prior to the close of 2023. As you might remember, this research stems from what we published in 2018, which demonstrated that the anti-CTLA-4 antibody worked best when paired with siforadenant or other A2A antagonists; during June, members of our team shared fresh preclinical results for siforadenant at both the Japanese Cancer Association and the American Association for Cancer Research Precision Cancer Medicine International Conference. Those findings showed that myeloid cells are involved, and that pairing siforadenant with immune checkpoint blockade results in generation of TH1 helper cells, which drove production of multiple pro-inflammatory cytokines. This backs up our previously published human clinical trial work that identified a myeloid gene expression signature serving as a biomarker for response. That biomarker — known as the adenosine gene signature — relies on quantifying expression across 8 myeloid genes. This preclinical evidence is encouraging to us, and we anticipate sharing clinical trial updates before the year is out. Turning to mupadolimab, our collaborator Angel Pharmaceuticals continues enrolling patients in a phase 1/1b clinical trial being run in China, testing mupadolimab both as a single agent and in combination with pembrolizumab among patients who have non-small cell lung cancer as well as head and neck squamous cell cancers. During the second quarter of 2023, we achieved meaningful progress carrying out our strategic initiatives. Our focus stays on pushing ITK inhibition forward as a novel immunotherapy strategy, and we aim to broaden that opportunity past lymphomas into a wide array of solid cancers and immune diseases. Several key upcoming milestones exist for our clinical programs, among them ongoing enrollment in our phase 1/1b soquelitinib trial, a meeting with the FDA this quarter regarding discussion of a registration phase 3 trial, launching a phase 1 monotherapy study of soquelitinib in solid tumors, and interim results from the phase 2 siforadenant trial in frontline, metastatic renal cell carcinoma. These programs give us numerous chances to tackle substantial patient needs across cancer and immune diseases. Having multiple shots on goal delivers considerable optionality for us, along with the ability to build shareholder value efficiently. To wrap up, we anticipate delivering program updates over the next several quarters. At this point, I'll hand things over to the operator so we can move into the Q&A session. Operator?

Roger Song

analyst
#5

Thanks a lot for fielding that, and congratulations on everything you've accomplished. Rich, we might have a few things to ask. Starting with the fresh results from the phase 1/1b study of soquelitinib that'll be presented at ASH — regarding the number of patients, how long they've been followed, or any other new details, what ought we to be watching for at ASH? Appreciate it.

Richard Miller

executive
#6

As you're aware, the ASH abstracts were only submitted a few days back. The ASH conference doesn't happen until December, so we're still a long way out. My expectation is that we'll refresh the data we hold by then, and in my view that would mean somewhere between 10 and 20 additional patients beyond those we shared on May 18th. On top of that, we're carrying out considerably more laboratory correlative work, which benefits us not just for T-cell lymphoma but also for solid tumors. We'll probably provide an update to the street ahead of ASH regarding how our phase 1b trial is progressing. I brought up the ASH conference simply as something familiar to most people. We've been issuing updates, clearly quite often, at conferences and on calls like these, and that will keep happening. For us, ASH is definitely a conference we'll be at.

Roger Song

analyst
#7

Roger, thanks for that. Regarding SIFO, by year-end you'll also have phase two RCC data available. Same kind of question — what ought we to anticipate there? Specifically, what might the next move be once that data lands? Richard, over to you.

Richard Miller

executive
#8

Well, Roger, I appreciate you raising that, since it lets me point out once more that the SIFO study involves siforadenant — an oral small molecule A2A antagonist — given alongside IPI and NIVO for first line renal cell cancer. There are two reasons we pair it with IPI NIVO. First, IPI NIVO demonstrates a plateau on the curve in renal cell cancer — on the PFS curves. Initially, the PD1 looked superior, yet CTLA-4 containing regimens appear to yield remissions that last longer and prove more durable. We, along with others, want to find out whether the plateau on those curves can be raised — meaning perhaps more people get cured. That's reason one. Reason two we feel good about this program: we've demonstrated, with data now quite consistent, that the optimal partner for an adenosine antagonist — an A2A antagonist — isn't an anti-PD1, rather an anti-CTLA-4. There's no time right now to explain the science underlying that, though I'd call it fairly clear-cut. CTLA-4 makes the best partner. Our animal data, published in 2018, proved this scientifically. Our frontline trial, while open — it's an open label study — lacks a concomitant control, yet we're quite familiar with work from MD Anderson, Vanderbilt, and other sites showing that if your response criteria is what's termed deep response — meaning complete responses plus partial responses exceeding 50% tumor regression — those so-called deep responses track very well with PFS. Across a couple of trials, the deep response rate for ipi nivo comes to 32%. That's the figure we aim to beat. My guess is that by year-end, I can't say for certain, we'll likely have 20, 30 patients in that category with some follow-up — treated and observed long enough for that determination to be made.

Roger Song

analyst
#9

Excellent. Thank you.

Richard Miller

executive
#10

Make sense?

Roger Song

analyst
#11

Great. Yeah, absolutely. Yeah, that's it. Thank you.

Aydin Huseynov

analyst
#12

Hi, good afternoon, everyone. Thanks for taking the questions, and congratulations on the progress this quarter. A couple of questions from me. You plan to meet with the FDA this quarter, which is within the next several weeks. The latest Phase 1b data for soquelitinib was cut off May 18th, so it's almost three months ago now. The kind of data that you're going to share with the FDA at that meeting, is it just the data before the cutoff date of May 18th, or will there be something more than that? Since a bit of time has gone by since then, you likely have additional patients who responded as well as some who didn't. So I'm wondering what sort of information you plan on providing to the FDA.

Richard Miller

executive
#13

Aiden, the information included in the submission we've given to the FDA basically covers everything up through May eighteenth. I can't say with complete certainty — it may extend a handful of days past that point, though not by much. That submission is filed quite a while ahead of time; it includes information across every dosage level. Keep in mind, what we shared back on May 18th concerned the 200 milligram dose, which is our optimal dose. We've now provided the FDA with the complete study — safety, efficacy, follow-up, pharmacokinetics, biomarker data, essentially all of it. Along with that, we included what we intend to do in phase 3, plus our strategy for studies that would come afterward. A few additional preclinical studies would still need to be completed. That's what the package contains. I'd say it's all fairly routine.

Aydin Huseynov

analyst
#14

Okay. Got it. Got it. Alright. Considering how soquelitinib works, and considering that it doesn't actually depend on checkpoint inhibition, how would you think about the potential for using soquelitinib in the future before PD-1, PD-L1, assuming it gets approved, and, you know, kind of, follow-on trials, follow-on kind of future use?

Richard Miller

executive
#15

Naturally, what we intend to do first is test it by itself. We're testing it in renal cell carcinoma patients, and there are several reasons why. First, renal is, renal is generally regarded as a tumor that responds to the immune system; every one of these patients will receive a PD-1 up front, and afterward they will relapse; that gives us an opportunity to examine monotherapy with soquelitinib in patients whose PD-1 has failed, who have relapsed. We can examine why they failed PD-1 and whether our monotherapy might rescue that. That will teach us a great deal. A number of biopsies will be built into that; now, the, the way our protocol, the way this protocol I'm describing is, is designed, once a patient progresses on our monotherapy, we're able to add a PD-1 to it; now, there's solid rationale for using a PD-1 alongside soquelitinib. The, the, the rationale has multiple parts. First, their mechanisms of action are independent. Their effects on the immune system differ. Second, exhaustion appears to be increasingly recognized as a key mechanism of resistance to PD-1. And the ITK inhibitor appears to prevent or reverse exhaustion, and our understanding of that is improving a lot. It's, it, we believe that's because of reduced tonic T-cell receptor signaling. The third reason is that ITK is in fact involved in the PD-1, PD-L1 negative signal, and that's, that is a really strong reason to combine PD-1 and ITK inhibitor together. Let me, let me repeat that, just so it's clear, 'cause it gets a bit confusing. PD-1, PD-L1, naturally, delivers a negative signal to a T-cell, and an anti-PD-1 blocks that. Well, the PD-1, PD-L1 negative signal needs ITK. If you blocked PD-1 or PD-L1, plus blocked ITK, you've completely disabled that negative signal, okay. There are many reasons to combine it with checkpoint blockade. I think that, since we've been testing it in T-cell lymphoma, and in T-cell lymphoma as a monotherapy, we observe tumors shrink. We observe large tumors shrink; we observe them remain gone for a long time; that's not because ITK is in the tumor, it's because of the impact on the host immune response. What we're observing in T-cell lymphoma, we believe, will be directly transferable to our work in solid tumors. Is that clear?

Aydin Huseynov

analyst
#16

Got it. Yeah, that's fine. Is there any chance at all, in your view, that soquelitinib could end up being given before PD1 down the road?

Richard Miller

executive
#17

That could happen, yes. That could happen, yes. What I mean is, a situation is imaginable in which the goal is boosting the number of T-cells moving into the tumor. After that, you'd want to introduce a PD-1, maybe to stop any unfavorable PD-1, PD-L1 interaction. That could happen, I'd say; as for how the drugs are sequenced, that's a question we are right now, we are right now in fact examining in animal models.

Aydin Huseynov

analyst
#18

Okay, that's useful. Do you know of any other earlier-stage companies working on ITK inhibitors, whether for blood cancers or solid tumors?

Richard Miller

executive
#19

I'm not aware of any other ITK inhibitor currently in clinical trials. And I'm glad you brought this up, because there's a great deal of misunderstanding out there. There have been. Soon after my team came up with ibrutinib, which also binds ITK, a lot of folks said, "Oh, there are ITK inhibitors," and so on and so forth. Many people claimed that, well, they have drugs that inhibit ITK. That isn't the problem, or that isn't what's difficult. What's difficult is creating an ITK inhibitor that doesn't affect any of those other kinases tied to T-cell differentiation, with the key one being RLK, or resting lymphocyte kinase. As far as I know, I'm not aware of any ITK inhibitor that only targets ITK and avoids RLK or any of the other closely related ones. Take ibrutinib: it does bind ITK weakly, but it binds RLK very strongly. That's no good, you don't want that. The bottom line is, I think soquelitinib is unique, and its uniqueness lies in how specific it is for ITK and how it spares the other kinases, particularly RLK. Now, that wasn't accidental. That's what the Corvus team intended to do when the company was started. That was the plan. We aimed to create an ITK inhibitor that was selective, particularly regarding RLK. That's a very challenging, that's a very challenging chemical problem, but we managed to do it. The reason that was our goal comes from genetic studies conducted in mice 20 years ago, which showed that if you selectively, specifically knock out ITK, you get this TH2 blockade and TH1 skewing, which produces greater antitumor activity. Our goal came about because of very selective genetic studies done two decades ago. We managed to achieve the selectivity and of course, now are, are moving it, advancing it in clinical trials. The reason we began with T-cell lymphoma is that ITK is present in T-cell lymphomas. That gave us a simple way to examine occupancy of the target in the tumor and so on and so forth; also, when we started, we didn't have as much information about solid tumors. Really, there's no reason to believe the mechanism of action is limited to T-cell malignancies. That said, T-cell malignancy is a good place to begin; it's clearly an unmet need, endpoints, especially in the relapse setting, happen quickly, on the order of months, a few months. For competitive reasons, for clinical trial reasons, it's a good place to begin, and we learned a lot about the biology of ITK; we were able to, I believe, get some good intellectual property around not only our, our drug, but methods of use. From where I sit, our competitive situation looks quite strong at this point, since we've carved out a fairly sizable area within this space.

Aydin Huseynov

analyst
#20

Thank you. Thanks — that's really useful. I've got just one more item, and it's more of a broad question. Would you ever think about offloading your stake in Angel Pharmaceuticals simply to bring in that capital and be able to concentrate on the U.S. business? And if so, what sort of value would you put on that Angel Pharmaceuticals stake?

Richard Miller

executive
#21

Let me begin by saying we're very fond of Angel Pharmaceuticals; the collaboration is excellent, they're accomplishing some impressive work over there, and it has definitely been a mutually beneficial relationship. Would we think about it? Sure, absolutely, we'd think about turning Angel into cash in some manner, should that become required and should the terms be attractive. As a matter of fact, that was among the strategies behind launching Angel back then, you know, 2 years ago when we got it going. The reasons we created Angel were to enable our global development, to reach into fast-growing markets in China, to speed up clinical development, and so on and so forth. It also provided us with another financing vehicle, so to speak, should we need one. Yes, we could do that. Incidentally, 49% of the stock in Angel belongs to us; so yes, we would think about that. You know, how would we put a value on it? Well, I'd value it far above what most people are, but, you know, the valuation of Angel at the time it started, the company raised $41 million from some Chinese biotech pharma companies, as well as some individuals. $41 million and had a post-money valuation of roughly $110 million, and that was 2 years ago. Since then, since that point in time, Angel now has 30 employees, roughly, a laboratory facility, and 2 clinical trials with both our ITK inhibitor and with mupadolimab going on. We think it's a lot more valuable today than it was 2 years ago.

Aydin Huseynov

analyst
#22

Understood. Many thanks. I truly appreciate all of the answers, and congrats on how far things have come; we're eager for the next updates.

Richard Miller

executive
#23

Thanks, Aiden.

Rosemary Lee

analyst
#24

Hello, Rosemary Lee here, filling in for Leah Watsky. We really appreciate you answering our questions. Regarding soquelitinib in TCL, could you make clear whether a date has been set for the FDA meeting, whether any steps must happen first, and whether you intend to share the feedback publicly?

Richard Miller

executive
#25

Rosemary, a date for that meeting has been set. We have submitted a data package, and yes, we would intend to communicate feedback to the street.

Rosemary Lee

analyst
#26

Excellent, thanks. Just a quick one — regarding the solid tumor program, will there be biomarker enrichment similar to what you're doing in TCL, or will enrollment begin without narrowing the population?

Richard Miller

executive
#27

My sense is we'll begin without narrowing. As the study is designed right now — is being designed right now — ALC isn't part of it. Still, I doubt that will cause problems, since the majority of these individuals, and this is a distinct illness where the initial setting is renal cell carcinoma at first or second relapse, those individuals tend to have fairly intact immune systems. That's quite a bit unlike the lymphoma group we treat, whose immune function is deeply compromised. It's a totally different type of population, and that's a really valid observation you're raising.

Jeff Jones

analyst
#28

Understood. Many thanks. That concludes our questions.

Jeff Jones

analyst
#29

Thanks, and well done on the quarters, everyone. I've got 2 questions for you. What amount of cash do you expect will be required to finish the phase three study in the form it's designed? And could you tell us what you're currently thinking regarding further indications for the ITK program, though in autoimmune and allergy, and what your approach is there?

Richard Miller

executive
#30

Thanks, Jeff. All right, 2 questions. We'll begin with the financial one. I'll ask Leiv, our CFO, to respond to that.

Leiv Lea

executive
#31

Jeff, this study is set up to include roughly 150 patients in a randomized format; our projection is that it will take place across approximately 40 sites around the world. As for what the study costs overall, perhaps $20 million. Enrollment and completion would require around 2 years.

Jeff Jones

analyst
#32

Thanks, that's great.

Richard Miller

executive
#33

All right. When it comes to autoimmunity and allergy, Jeff, that's an area we're heavily involved in; we keep working with a range of animal models. A protocol focused on atopic dermatitis is actually in the process of being set up. We likely wouldn't kick that off until early next year. We have a whole second- and third-generation effort underway, in which we're creating additional ITK inhibitors that share similar selectivity yet have a greater tendency to influence, say, TH2 rather than TH17 or TH1. We have certain concepts for producing even superior compounds for allergy. Naturally, we're also attempting to address the problem of not wanting to have both a cancer drug and an allergy, you know, an autoimmune drug. You know, we are—we're mindful of and worried about those pricing concerns. But we, we believe that, given, given the technology and given the chemistry we've built up, we can create drugs, ITK inhibitors, with features that are more desirable, especially aimed at autoimmunity, particularly aimed at autoimmunity. So that's roughly our approach; but listen, I mean, as you're well aware, with a possible phase three trial coming up, our ongoing siforadenant study, the solid tumor study, mupadolimab being run by Angel, we, we have, you know, we have a great deal on our plate at the moment. There's no doubt that with additional resources, we'd be in the clinic with allergy right now, allergy and autoimmunity right now. No doubt about it; we simply believe that the cancer indications, especially for us, since that's where our expertise lies, we feel that's, you know, a superior investment for us, at this time.

Jeff Jones

analyst
#34

Excellent. We really appreciate that insight, everyone.

Richard Miller

executive
#35

Thanks, Jeff. Very well.

Richard Miller

executive
#36

That's fine, no problem. It looks like there aren't any further questions. To start, I want to thank all of you for joining this call; we're eager to share news about what's ahead during our future calls. Thanks so much, everybody.

Operator

operator
#37

That brings us to the end of today's conference call. You can go ahead and disconnect your lines now. Thanks for joining us, and have a pleasant day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.